All In Biotech

NDA 209463 · Hikma

Pantoprazole Sodium

Pantoprazole Sodium · Intravenous

Last checked: Nov 20, 2026Latest source record: Jul 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jun 30, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

231

49 Phase 3, 17 recruiting

FAERS reports

256,989

213,977 serious, 29,169 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 23, 2026.

Pantoprazole Sodium for Injection is a proton pump inhibitor (PPI) indicated in adults for the following: • Short-term treatment (7 to 10 days) of gastroesophageal reflux disease (GERD) associated with a history of erosive esophagitis (EE). ( 1.1 ) • Pathological hypersecretion conditions, including Zollinger-Ellison (ZE) syndrome. ( 1.2 ) 1.1 Gastroesophageal Reflux Disease Associated with a History of Erosive Esophagitis Pantoprazole Sodium for Injection is indicated for short-term treatment (7 to 10 days) of adult patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE). Safety and efficacy of Pantoprazole Sodium for Injection as a treatment of patients with GERD and a history of EE for more than 10 days have not been demonstrated. 1.2 Pathological Hypersecretion Including Zollinger-Ellison Syndrome Pantoprazole Sodium for Injection is indicated for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults.

Mechanism: Pantoprazole is a PPI that suppresses the final step in gastric acid production by covalently binding to the (H + , K + )-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the (H + , K + )-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 30, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • PANTOPRAZOLE SODIUM · PANTOPRAZOLE SODIUM EQ 40MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Pantoprazole" as an intervention, any sponsor and status, largest first.

All 231 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue21,188
  • off label use19,113
  • nausea18,251
  • diarrhoea17,956
  • dyspnoea17,581
  • drug ineffective17,560
  • pain15,804
  • headache13,606
  • vomiting13,065
  • arthralgia12,489
  • pyrexia11,802
  • acute kidney injury11,771

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004656
20051,119
20061,143
20071,069
20081,476
20091,621
20102,325
20113,570
20124,716
20133,829
20145,617
20159,299
201611,321
201712,482
201819,842
201924,617
202022,959
202123,429
202225,009
202321,427
202422,857
202521,334
202615,268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pantoprazole Sodium* (Pantoprazole Sodium)

2024 spending

$321M

Beneficiaries

6,692,955

25,600,657 claims

Per beneficiary

$48

$0.20 per unit

View as table
YearSpending
2020$315,731,226
2021$375,118,537
2022$364,471,013
2023$384,044,956
2024$320,865,497

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 616 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.